Onkológia 4/2014

First line treatment of metastatic renal cell cancer in 2014

Multiple vascular endothelial growth factor (VEGF) and mammalian target of rapamycin (mTOR) inhibitors showed improvement in progression-free survival (PFS) in the first-line setting of the patients with metastatic renal cell cancer (mRCC). High-dose interleukin still remains a valid option in selected group of patients with clear cell histology and, currently, it is only treatment with potential to achieve durable complete responses. Appropriate patient’s selection that could personalize treatment could help to give the best effective and the least toxic treatment to individual patient. Thus, identification of predictive factors for treatment selection is a priority of current research. There is still an option to observe selected group of the patients with mRCC. The article is a review of current 1st line treatment options in the patients with mRCC.

Keywords: metastatic renal cell cancer, 1st line treatment, targeted therapy.